Day One Biopharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Day One Biopharmaceuticals, Inc. (DAWN) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-95.50-188.92-142.18-72.75-40.51
Depreciation & Amortization2.030.380.530.200.16
Stock Based Compensation48.2639.3427.2413.320.53
Change in Working Capital26.48-0.75-2.33-2.24-0.36
Change in Accounts Receivable-13.880.000.000.000.00
Change in Inventory-3.240.000.000.000.00
Change in Accounts Payable0.692.32-1.481.540.13
Change in Other Working Capital42.917.108.051.15-0.49
Other Operating Activities-59.3942.4336.1426.2526.69
Net Cash from Operating Activities-78.11-146.85-109.87-48.54-13.49
Investing Activities
Capital Expenditures-2.17-0.220.03-8.00-0.09
Purchases of Investments-658.62131.60-255.050.000.00
Sales/Maturities of Investments393.89-443.84-255.05-8.000.00
Other Investing Activities35.900.000.00-8.000.00
Net Cash from Investing Activities-230.99128.38-255.07-8.00-0.09
Financing Activities
Common Stock Issued178.18164.00162.25167.360.00
Other Financing Activities25.110.000.008.320.00
Net Cash from Financing Activities203.29164.00165.90297.1229.98
Summary
Net Change in Cash-105.82145.52-199.05240.5816.40
Cash at Beginning of Period230.7885.26284.3143.730.00
Cash at End of Period124.97-590.6985.26284.310.00
Free Cash Flow-80.28-146.85-109.90-48.54-13.58
Supplemental Disclosures
Income Taxes Paid1.900.000.000.000.00